N@N

PATIENT HOME MONITORING ANNOUNCES CEO INTERVIEW ON LEADING BUSINESS RADIO PROGRAM

^{Published on 2011-02-10 13:10:36 - Market Wire}
 

SAN FRANCISCO, Feb. 10 /CNW/ - Patient Home Monitoring (PHM) (TSXV:PHM), a company focused on in-home cardiology healthcare services, today announced that as part of a series on emerging growth companies, Executive Leaders Radio interviewed Ed Berenblum, the Company's Chief Executive Officer.  Executive Leaders Radio is the leading business radio show from Greater Philadelphia to Northern Virginia (including Pennsylvania, New Jersey, Delaware, Maryland, Washington D.C. and Virginia).

Mr. Berenblum's interview covers a brief history on PHM, as well as his professional background and experience before joining the Company in 2010. The interview will air on Saturday, February 12th on WHFS 1580AM and will also stream live on their website at [ www.bigtalker1580.com ] from 10:00-11:00 am EST and at that same time on Yahoo radio and AOL radio.  The interview will also be posted at [ www.executiveleadersradio.com ] and on PHM's website within the next two weeks.

For additional information please refer to the Company's website and complete filings at [ www.sedar.com ].

About PHM
PHM is a healthcare services company focused on providing in-home testing for patients on blood thinner medications such as Coumadin or warfarin. PHM's unique value proposition, for cardiology groups that manage patients on Coumadin, focuses on systemization to enroll patients in patient self testing (PST). This unique, systemized approach creates an opportunity for physician groups to operate more efficiently, increasing revenue to their clinic while providing a higher standard of care for patients.

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of PHM and anticipated events or results, are assumptions based on beliefs of PHM's senior management as well as information currently available to it. While these assumptions were considered reasonable by PHM at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue operations, decline of reimbursement rates, dependence on few payors, possible new drug discoveries, a novel business model, dependence on key suppliers, granting of permits and licenses in a highly regulated business, competition, low profit market segments as well as general economic, market and business conditions, and could differ materially from what is currently expected.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.